UBS Group Forecasts Strong Price Appreciation for Acadia Healthcare (NASDAQ:ACHC) Stock

Acadia Healthcare (NASDAQ:ACHC) had its price objective lifted by UBS Group from $24.00 to $27.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price objective would indicate a potential upside of 15.19% from the company’s current price.

A number of other analysts have also issued reports on the company. TD Cowen raised their target price on Acadia Healthcare from $22.00 to $24.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings reissued a “sell (d)” rating on shares of Acadia Healthcare in a research report on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Acadia Healthcare from $33.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, December 3rd. KeyCorp reduced their price target on shares of Acadia Healthcare from $30.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, December 3rd. Finally, Cantor Fitzgerald set a $17.00 price objective on shares of Acadia Healthcare in a report on Wednesday, December 3rd. Seven research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Acadia Healthcare currently has an average rating of “Hold” and an average price target of $20.69.

Acadia Healthcare Price Performance

NASDAQ ACHC opened at $23.44 on Thursday. The company has a market cap of $2.16 billion, a P/E ratio of -1.92, a P/E/G ratio of 7.67 and a beta of 0.89. Acadia Healthcare has a 1 year low of $11.43 and a 1 year high of $33.58. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 1.27. The company has a fifty day simple moving average of $14.82 and a 200 day simple moving average of $18.57.

Acadia Healthcare (NASDAQ:ACHC) last released its earnings results on Wednesday, February 25th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. The firm had revenue of $821.46 million during the quarter, compared to analyst estimates of $800.10 million. Acadia Healthcare had a negative net margin of 33.29% and a positive return on equity of 6.53%. The business’s revenue was up 6.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.64 EPS. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS. On average, sell-side analysts predict that Acadia Healthcare will post 3.38 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ACHC. Alpine Global Management LLC bought a new position in Acadia Healthcare during the fourth quarter worth about $174,000. Aristides Capital LLC bought a new position in shares of Acadia Healthcare during the 4th quarter worth approximately $196,000. Invesco Ltd. boosted its stake in Acadia Healthcare by 58.7% in the 4th quarter. Invesco Ltd. now owns 727,846 shares of the company’s stock valued at $10,328,000 after buying an additional 269,140 shares in the last quarter. Wellington Management Group LLP grew its position in Acadia Healthcare by 24.9% in the fourth quarter. Wellington Management Group LLP now owns 11,774,308 shares of the company’s stock valued at $167,077,000 after acquiring an additional 2,350,760 shares during the period. Finally, SummitTX Capital L.P. acquired a new position in Acadia Healthcare during the fourth quarter worth $821,000.

Key Acadia Healthcare News

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Q4 revenue topped estimates and EPS beat consensus, driving a strong intraday jump; management provided FY2026 and Q1 2026 guidance that gave investors a clearer outlook. Acadia Healthcare’s (NASDAQ:ACHC) Q4 CY2025 Sales Top Estimates, Stock Jumps 10.8%
• Positive Sentiment: The company posted its Q4 earnings presentation and materials, helping investors parse revenue mix, margin drivers and the path to management’s FY26 targets. Acadia Healthcare Company, Inc. 2025 Q4 – Results – Earnings Call Presentation
• Positive Sentiment: Multiple brokerages raised price targets and maintain buy/outperform stances—RBC to $28 (outperform), UBS to $27 (buy) and TD Cowen to $24 (buy)—which increases buy-side conviction and likely supported the rally. Benzinga: Analyst Price-Target Updates
• Positive Sentiment: Analysts and commentary highlighted improving execution and embedded EBITDA opportunities under returning management, reinforcing the view that operational fixes could restore profitability. TipRanks: Buy Rating on Improving Execution
• Neutral Sentiment: Aggregated analyst coverage: a Benzinga deep-dive summarizes 17 analyst ratings and consensus perspectives — useful for context on how Street expectations are shifting but not a single catalyst. Acadia Healthcare Co Stock: A Deep Dive Into Analyst Perspectives (17 Ratings)
• Negative Sentiment: Short interest remains very large (~32.45M shares as of mid‑Feb, ~35.9% of float) with a ~7.3 days-to-cover ratio — this high short position increases the risk of volatile trading, squeezes, or pressure if execution disappoints. (short-interest reports summarized in filings and market data)

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.